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Abstract
Glucocorticoids play a pivotal role in the proliferation of osteoblasts, but the underlying mechanism has not been
successfully elucidated. In this report, we have investigated the molecular mechanism which elucidates the inhibitory effects
of dexamethasone on murine osteoblastic MC3T3-E1 cells. It was found that the inhibitory effects were largely attributed to
apoptosis and G1 phase arrest. Both the cell cycle arrest and apoptosis were dependent on glucocorticoid receptor (GR), as
they were abolished by GR blocker RU486 pre-treatment and GR interference. G1 phase arrest and apoptosis were
accompanied with a p53-dependent up-regulation of p21 and pro-apoptotic genes NOXA and PUMA. We also proved that
dexamethasone can’t induce apoptosis and cell cycle arrest when p53 was inhibited by p53 RNA interference. These data
demonstrate that proliferation of MC3T3-E1 cell was significantly and directly inhibited by dexamethasone treatment via
aberrant GR activation and subsequently P53 activation.
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Introduction
Glucocorticoids (GCs) are the most frequently used anti-
inammatory and immunosuppressive drugs in clinic to treat a
variety of diseases including inflammation, cancer, and autoim-
mune disorders [1]. However, it has been found that prolonged
and/or overdose GCs treatment is the most common cause of
osteonecrosis [2] and the third most common cause of osteoporosis
[3]. It has been reported that GCs could induce apoptosis of
osteoblasts and inhibit its proliferation, thus leading to osteoporosis
and osteonecrosis [4]. However, the molecular mechanism of GCs
involved in apoptosis and proliferation inhibition of osteoblast is
still poorly understood.
The effects of GCs are primarily considered to be mediated by
cytosolic glucocorticoid receptor (GR) activation [5], but the
events leading from the activated GR to growth arrest are not yet
elucidated completely. Previous studies have reported that GCs
treatment induce osteoblast apoptosis by enhancing the expression
of BH3-only protein Bim [6], down-regulation of TIMP-1 [7], and
activation of glycogen synthase kinase 3 beta (GSK-3b) [8]. But to
the best of our knowledge, there is no direct relationship between
GR and these proteins, such as transcription-control or protein-
protein interaction. We reviewed previous studies in terms of the
relationship between GR activation and apoptosis, and these
studies has reported that p53 [9], granzyme A [10–11] or
Glucocorticoid-induced leucine zipper (GILZ) [12–13] may be the
downstream molecules of GR activation.
We postulate that GC activates GR, and then leads to activation
of P53, granzyme A or GILZ, thereby inducing osteoblasts
apoptosis and cell cycle arrest. The results of this study indicate
that GR activation indeed up-regulates the expression of P53 and
its downstream molecule, which results in growth inhibition.
Materials and Methods
Ethical Statement
N/A.
Reagents
Dexamethasone, and RU486 (mifepristone) were obtained from
Sigma (Sigma–Aldrich Ltd, Poole, UK). Dexamethasone was used
in a concentration gradient from 0.001 mMt o1 0 mM. Final
concentration of RU486 was 10 mM. Control in all experiments
was vehicle (ethanol) unless otherwise indicated. Cell counting kit
(CCK-8) were obtained from Dojindo (Dojindo Molecular
Technologies Inc, Gaithersburg, MD). Antibody of b-action,
caspase-3, p53, PUMAand p21were purchased from cell signaling
technology (CST, Danvers, MA), NOXA, granzyme A and GILZ
were purchased from Abcam (Abcam, Cambridge, UK). Annexin
V-FITC apoptosis determining kit were purchased from BD
PharMingen (BD Biosciences, San Jose, CA). TUNEL assay was
purchased from Roche Applied Science (Mannheim, Germany).
Lipofectamine RNAi MAX was purchased from Invitrogen
(Invitrogen Co., Carlsbad, California).
Cell Culture
The murine osteoblastic cell line MC3T3-E1 was obtained from
American Type Culture Collection (ATCC, Rockville, MD, USA).
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USA) supplemented with 10% FBS, 20 mM HEPES, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 50 mg/ml ascorbic acid
Cellswereincubatedinahumidincubatorat37uC(95%O2and5%
CO2) and maintained in a subconuent state unless otherwise
indicated.
Cell Transfection
For the experiments with RNA interference (RNAi), a mouse
P53 and GRa specific double-stranded, small interfering (si) RNA
was synthesized (Shanghai Genepharma Co.,Ltd. Shanghai,
China). Two of p53 siRNA molecules,sip53-1 and sip53-2, were
selected: Sip53-1: (forward) 5- CCACUUGAUGGAGA-
GUAUUTT -3 and (reverse) 5- AAUACUCUCCAUCAA-
GUGGTT-3, and sip53-2: (forward) 5- GACCUAUCCUUAC-
CAUCAUTT -3 and (reverse) 5-
AUGAUGGUAAGGAUAGGUCTT -3. Two of GRa siRNA
molecules, siGR-1 and siGR-2, were selected: siGR-1(forward) 5-
GGAGAGGACAACCUGACUUTT-3 and(reverse) 5-AAGU-
CAGGUUGUCCUCUCCTT-3, siGR-2(forward) 5- CUGCAU-
GUAUGACCAAUGUTT -3 and(reverse) 5- ACAUUGGU-
CAUACAUGCAGTT -3.In addition, siRNA molecules that
exhibited no homology to the mouse genome sequence were
selected as negative controls (forward) 5- UUCUCCGAACGU-
GUCACGUTT -3 and (reverse) 5- ACGUGACACGUUCGGA-
GAATT -3 (siRNA control group, ‘‘siC’’). A further untreated
group of MC3T3-E1 cell cultures served as untreated control
group (FBS group). Lipofectamine RNAi MAX was used to
introduce the siRNA into the MC3T3-E1 cells according to the
manufacturer’s instruction.
Cell Proliferation Assay
The MC3T3-E1 cells were inoculated at 2610
3 cells per well in
96-well plates. To assess the effects of dexamethasone on cell
proliferation, the cells were incubated in growth medium or
conditioned medium for 24 h at the concentration gradient from
0.001 mMt o1 0 mM. The sample cells were quantified using
WST-8 assay, according to the instructions. Briefly, 10 ml of 2-(2-
methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-
2H-tetrazolium (WST-8) solution reagent was added to 100 mlo f
culture medium in each well. After incubation for 2.5 h at 37uC,
The absorbance of each well was read at a wavelength of 450 nm
on a microplate reader. The measurements were represented by
the means of at least three independent experiments, with each
data point based upon three replicates.
Cell Death Detection
The MC3T3-E1Cells were seeded subconfluently into 12-well
plates and treated with conditioned medium for 24 h at the
concentration gradient from 0.001 mMt o1 0 mM. Cells were
trypsinized and pelleted with cellular supernatant for 5 min at
400 g. After pellet was resuspended in 60 mL media, cell death
rates were determined by counting cells using a hemocytometer
after addition of Trypan blue, which stained the cytoplasm of dead
cells but not live cells. Cell death rate (%)=number of dead cells/
number of total cells (6100%).
Cell Cycle Analysis
Cells were analyzed for their cell cycle distribution by flow
cytometry. After being treated with dexamethasone for 48 h, the
adherent cells were washed once with PBS, then trypsinized, and
collected by centrifugation at 400 g for 5 min. The cells (106 cells
per sample) were fixed in 4 ml of cold 70% ethanol at 220uC
overnight. After centrifugation at 4006g for 5 min, cell pellets
were incubated with 0.5 ml of PBS containing 100 g/mml RNase
and 5 mg/ml propidium iodide (PI) at 37uC for 30 min. Cell cycle
distribution was analyzed by measuring DNA content using a flow
cytometer (Beckman Coulter, Inc.Fullerton, CA).
Assessment of Apoptosis
FITC Annexin V apoptosis determining kit was used to
quantitatively determine the percentage of cells within a popula-
tion that are actively undergoing early apoptosis per manufacture’s
instruction. Briefly, the cells were collected, washed twice with
Annexin binding buffer and incubated with Annexin V-FITC and
propidium iodide under the manufacturer’s recommended condi-
tions. Cells that stain positive for FITC Annexin V and negative
for PI were considered undergoing early apoptosis.
TUNELassaywasperformedusingtheinsitucelldeathdetection
kitaccordingtothemanufacturer’sinstructions.Briefly,MC3T3-E1
cellswereplatedontocoverslipsandculturedovernight.Aftertreated
with various stress stimuli for 24 hours cells were fixed in 4%
paraformaldehyde for 30 min at room temperature and permeabi-
lizedin0.1%TritonX-100for2 minat4uC.Cellswerethenstained
with fluorescein isothiocyanate (FITC)-conjugated terminal deox-
ynucleotidyl TUNELreactionmixture for1 hatroomtemperature
and incubated with DAB for 2 min. All dilutions were performed in
PBS, and samples were analyzed and recorded by an OLYMPUS
FLUOVIEW microscope.
Real-time Polymerase Chain Reaction (PCR)
The total RNA was extracted from the cells using TRIzol
reagent (Invitrogen, Carlsbad, CA, USA) and then reverse-
transcribed (Promega, Madison, WI, USA) following manufac-
ture’s protocol. The detection of P53 or GRa mRNA levels was
performed by real-time RT-PCR (ABI PRISM 7900 Sequence
Detection System, Applied Biosystems, Foster City, CA, USA).
The primer were as follows: 5- TGTAATAGCTCCTG-
CATGGGG -3 (forward) and 5- TGCTATGCTTTGCTCCT-
GATCTG -3 (reverse) primers for P53, 5-
TGCTATGCTTTGCTCCTGATCTG (forward) and 5-
TGTCAGTTGATAAAACCGCTGCC -3 reverse primers for
GRa, 5- ATCATGTTTGAGACCTTCAACA (forward) and 5-
CATCTCTTGCTCGAAGTCCA -3 reverse primers forb-actin.
Quantification of the P53 or GRa mRNA expression was
calculated using the standard curve method.
Western Blot Analysis
Whole-cell extracts were prepared using Triton lysis buffer
(50 mM Tris–HCl, pH 8.0 containing 150 mM NaCl, 1% Triton
X-100, 0.02% sodium azide, 10 mM EDTA, 10 lg/ml aprotinin,
and 1 lg/ml aminoethylbenzenesulfonyl fluoride). After the lysates
were centrifuged for 12 min at 3,000 g to remove debris, protein
concentrations were determined using the Bradford protein assay.
20–40 micrograms of protein from each cell layer homogenate was
loaded onto a 10% or 12% polyacrylamide gel and transferred to a
PVDF membrane. The membranes were blocked with 5% nonfat
milk and incubated with primary antibodies. After extensive
washing, the membranes were re-probed with peroxidase conju-
gated secondary antibody. Blots were processed using an ECL kit
and exposed to film Controls for protein loading were made by b-
actins as the internal standard.
Statistical Analysis
All data were expressed as means 6 SD. The differences
between groups was analyzed by one-way analysis of variance
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18.0 for windows. P-value (P) ,0.05 was considered statistically
significant.
Results
Dexamethasone Inhibit MC3T3-E1 Proliferation and
Induce the Cell Death
The 24-hour exposure of murine osteoblast MC3T3-E1 to
0.001, 0.01, 0.1,1.10 mmol/L DEX respectively decreased cell
proliferation in a concentration-dependent manner (Figure 1A)
Compared with ethanol control and low concentration dexameth-
asone, 1 and 10 mmol/L DEX reduced cell proliferation by
55.0164.01% and 60.0266.02%, respectively. To further confirm
whether DEX toxicity inhibits cell proliferation, we used Typan
blue incorporation to test dead cells. Typan blue assay suggested
that treatment with 1 and 10 mmol/L dexamethasone remarkably
increased dead cell population to 6.1060.00% and 7.7660.01%,
respectively (Figure 1B).
DEX-induced MC3T3-E1apoptosis and G0/G1 Arrest are
Abolished by RU486 Pre-treatment
To determine whether the inhibitory effect can be attributed to
apoptosis and cell cycle arrest, and whether the effect results from
GR activation, we treated MC3T3-E1 cells with PBS (control
group), 1 mmol/L dexamethasone (DEX group), RU486 (RU486
group), and 1 mmol/L dexamethasone plus 10 mmol/L RU486
(DEX+RU group) respectively. The apoptotic cells to total cells
ratio was significantly (P,0.05) higher in DEX group
(12.160.04%) as compared to 3.0160.04% in the control group,
3.5460.05% in the RU486 group, and 5.3660.03% in the
DEX+RU group. (Figure 2 A) The level of the cleaved-caspase 3
protein was significantly up-regulated in the DEX group, when
compared to that in other groups. (P,0.05) (figure 2B). By adding
RU486 2 hours prior to dexamethasone treatment, we blocked the
GR and the apoptosis effect associated with GR activation.
To assess the change of cell cycle induced by dexamethasone in
MC3T3-E1 cells, the cell nuclei were stained with propidium
iodide and the cell cycle was analyzed through flow cytometry.
The percentage of cells in the G0–G1 phase increased significantly
(P,0.05) to 84.6761.61% in the DEX group, as compared to
64.6762.65% in the control group, 68.5.62.65% in the RU486
group, and 68.0060.76% in the DEX+RU group, respectively.
The percentage of cells in the S phase was decreased significantly
(P,0.05) to 8.9061.00% in the DEX group as compared to
27.6760.58% in the control group, 24.0061.00% in the RU
group, and 23.8361.26% in the DEX+RU group, respectively.
(Figure 2 C).
GRa Gene Silencing Inhibited the G0–G1 Arrest and
Apoptosis Induced by DEX
To investigate GRagene function, we tried to silence this gene
in MC3T3-E1 cells using siRNA targeting GRamRNA. The
elimination of the GRamRNA and protein in MC3T3-E1 cell
cultures was achieved as determined by real-time PCR (Fig. 3A)
and Western blotting (Fig. 3B), respectively. When compared to
those in untreated and siRNA control (siC) group, the mRNA and
protein expression level of GRa decreased significantly (P,0.05)
in the siGR-1 and siGR-2 group. On the other hand, the b-actin
did not vary significantly between the groups.
To further determine the role of GR in DEX-induced apoptosis
and cell cycle, we treated MC3T3-E1 cells with PBS (control
group), 1 mmol/L DEX (DEX group), siGR-1 (siGR-1 group),
1 mmol/L DEX plus siGR-1 (DEX+siGR-1 group) respectively.
Cleaved Capase-3 was used to characterize apoptosis of these
groups. Western blot show DEX can significantly activate caspase-
3 and then up-regulate cleaved Capase-3 expression, this effect can
be reversed by gene silencing of GRa (Figure 3C). TUNEL
staining was also performed which shows apoptotic cells increased
in DEX group, this effect can abolisded by GR geen siliencing as
demonstrated in the DEX+siGR-1 group (Fig. 3D). The apoptotic
cells to total cells ratio was significantly (P,0.05) higher in DEX
group (12.3460.65%) as compared to 4.1160.08% in the control
group, 6.2360.27% in the siGR-1 group, and apoptotic cell ratio
decreased significantly when GRawas silenced (6.9460.37%).
(Figure 3E).
The percentage of cells in the G0–G1 phase increased
significantly (P,0.05) to 81.1464.77% in the DEX group as
compared to 67.2663.65% in the control group, 68.462.65% in
the siGR-1 group, and 69.3460.76% in the DEX+siGR-1 group.
The percentage of cells in the S phase was decreased significantly
(P,0.05) to 11.0960.86% in the DEX group as compared to
24.7461.58% in the control group, 21.7562.00% in the siGR-1
group, and 20.8361.13% in the DEX+siGR-1 group. (Figure 3E).
Figure 1. Dexamethasone dose-dependently inhibit MC3T3-E1 proliferation and induce cell death. (A) Proliferation of MC3T3-E1 cells
was measured by CCK8 (colorimetric cell counting kit-8) after cells were treated with 0, 0.001,0.01,0.1, 1.0 and 10.0 mmol/L dexamethasone for
24 hours. treatment with 1 and 10 mmol/L DEX remarkably reduced cell proliferation. B) Cell death was measured by typan blue incorporation after
cells were treated with 0, 0.001,0.01,0.1, 1.0 and 10.0 mmol/L dexamethasone for 24 hours. treatment with 1 and 10 mmol/L dexamethasone
remarkably increased dead cell population Values are means+SEM (n=3). *P, 0.05 vs corresponding untreated controls.
doi:10.1371/journal.pone.0037030.g001
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Treatment
To identify the downstream signaling pathways of GR
activation, we performed Western blot analysis of proteins affected
by GR activation such as granzyme A, GILZ and p53,respectively.
This was done when MC3T3-E1 cells was treated with 0, 0.001,
0.01, 0.1, 1.0 and 10.0 mmol/L DEX, respectively. The levels of
granzyme A and GILZ did not increased, but the expression of
P53 was dose-dependently up-regulated (Figure 4A). These results
suggest that P53 is a mediator of GR activation and growth
inhibition.
To further confirm that and identify downstream signaling
pathways of P53, we performed western blot analysis of apoptosis
and cell cycle associated proteins NOXA, PUMA and p21. In the
DEX group, the level of the p53 protein was up-regulated, when
compared with that of the control group, siGR-1 group and siGR-
1+DEX group, which was consistent with the previous results. The
level of the NOXA, PUMA and P21 protein was also up-regulated
in the DEX group which suggested that P53 is a key molecular
between GR activation and NOXA, PUMA and P21 up-
regulation. For comparison, b-actin protein was used as an
internal reference, which did not vary remarkably. (Figure 4B).
p53 Gene Silienc by siRNA can Reverse DEX Induced
Apoptosis and Cell Cycle Arrest of MC3T3-E1 Cells
To investigate the p53 gene function, we tried to silence this
gene in MC3T3-E1 cells with siRNA targeting p53 mRNA. The
knockdown of the p53 mRNA in MC3T3-E1 cell cultures was
achieved as verified by RT-PCR and western blot (Fig. 5A, B).
The protein expression level of p53 decreased significantly
Figure 2. DEX-induced MC3T3-E1 apoptosis and G0/G1 arrest are abolished by RU486 pre-treatment. (A) Assessment of apoptosis in
MC3T3-E1 cells using flow cytometry with Annexin V-FITC/PI staining. The apoptotic cells to total cells ratio was significantly (P,0.05) higher in DEX
group compared to the control group, RU486 group, DEX+RU group. DEX+RU group and RU486 group were implemented through 2-hour
pretreatment of RU486 and then DEX/ethanol treatment. (B) The level of the cleaved-caspase 3 protein was significantly up-regulated in the DEX
group, when compared to that in other groups. DEX+RU group and RU486 group (C) Cell cycle analysis using flow cytometry with PI staining,
showing representive histograms of MC3T3-E1 cells in control group, DEX group, RU486 group, DEX+RU group. The distribution of the cell cycle
phase was expressed as the percentage of cells in the G0–G1 phase, S phase and G2-M phase of the cell cycle. The proportion of cells in the S phase
decreased markedly in the DEX group in comparison to the control group, RU486 group, DEX+RU group. The proportion of cells in the G0–G1
significantly increased in the DEX group.(P,0.05) Control group: cells treated with ethnol for 24hours. DEX group: cells treated with 1 mmol/L
dexamethasone for 24 hours. RU486 group: cells pre-treated 2 hours by10mmol/L RU486 and then treated with ethnol for 24 hours. DEX+RU group:
cells pre-treated 2 hours by10 mmol/L RU486 and then treated with 1 mmol/L dexamethasone for 24 hours.
doi:10.1371/journal.pone.0037030.g002
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e37030Figure 3. GRa Gene Silencing inhibited MC3T3-E1 G0–G1 arrest and apoptosis induced by DEX. (A) Real time PCR examination of MC3T3-
E1 cells in which the GRagene function was silenced by siRNA (siGR-1, siGR-2) targeting GRamRNA; the mRNA expression level of GRain the siGR-1and
siGR-2 groups decreased significantly (P,0.05) compared to that in the FBS group and the siC group. (B) Examination of the protein expression level
of the GRagene by Western blotting following treatment with the indicated siRNA molecules siGR-1 and siGR-2. The protein expression level of
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the siRNA negative control groups and untreated groups. For
comparison, the b-actin protein did not vary significantly between
the groups.
We then treated MC3T3-E1 cells with PBS(control group ),
1 mmol/L dexamethasone(DEX group ), MC3T3-E1 cell silencing
the p53 Gene (sip53-1 group), 1 mmol/L dexamethasone plus
siRNA (DEX+sip53-1 group) respectively. Cleaved Capase-3 was
used to characterize apoptosis of these groups. Western blot show
DEX can significantly up-regulate cleaved Capase-3 expression,
this effect can be reversed by gene silencing of p53 (Figure 5C).
TUNEL staining was also performed which shows apoptotic cells
increased in DEX group, but when p53 was silenced apoptotic
cells decreased significantly (Fig. 5D).The apoptotic cells to total
cells ratio was significantly (P,0.05) higher in DEX group
(13.1260.75%) as compared to 5.1360.17% in the control group,
5.7460.56% in the sip53-1 group, and this effect can abolisded by
p53 geen siliencing (Figure 5E).
The percentage of cells in the G0–G1 phase increased
significantly (P,0.05) to 81.4463.56% in the DEX group as
compared to 66.3662.44% in the control group, 67.5163.54% in
the siGR-1 group,and 70.6861.67% in the DEX+siGR-1 group.
The percentage of cells in the S phase was also decreased
significantly (P,0.05) to 9.5461.07% in the DEX group as
compared to 23.7360.97% in the control group, 26.5761.56% in
the siGR-1 group, and 22.3461.34% in the DEX+ siGR-1 group.
(Figure 5E).
Discussion
In this study, we have illustrated for the first time that GR
activation by dexamethasone up-regulates P53 in MC3T3-E1
osteoblast cell line, thereby enhancing the transcriptional activatity
of P53. And it ultimately induces MC3T3-E1 cells apoptosis and
cell cycle arrest.
It has been reported that GCs have potent inhibitory effects on
osteoblast proliferation [4]. Earlier research studies have suggested
that GR activation play a pivotal role in GCs induced apoptosis
[11]. In this study, we found that dexamethasone treatment not
only induces MC3T3-E1 apoptosis but also arrest G1 cell cycle,
which was also dependent on GR activation. We demonstrated
that dexamethasone treatment can increase apoptosis more than
two fold, which was consistent with previous studies [11].
However, Smith disclosed that dexamethasone arrest MC3T3-
E1 at G2/M phase [14–15], which did not comply with our
results. This may be because the culture condition in our
experiments differs from that in the previous study.
The effect of GR activation by glucocorticoids has long been a
research focus. It is well accepted that the effect and molecular
mechanism of GR activation is cell context specific. For example,
it has been reported that GR activation by dexamethasone
promotes survival and inhibits apoptosis of mammary epithelial
cells through transcriptional induction of serum and GC-inducible
protein kinase-1 (SGK-1) and mitogen-activated protein kinase
phosphatase-1 (MKP-1) [16]. On the contrary, other studies have
reported that GR activation in thymocytes and lymphocytes
triggers apoptosis through cathepsin B [17]. In osteoblasts, there is
a consensus that glucocorticoid treatmentinduces osteoblast death
both in vivo and in vitro [11,18]. It has been reported that several
important protein participate in the apoptosis or cell cycle arrest of
osteoblast [6–8,14] but to the best of our knowledge, there is no
transcription-control or protein-protein interaction between GR
and these proteins. So we need to further investigate the
downstream executive molecules.
GZMA, one of the apoptotic effectors and direct transcriptional
targets of glucocorticoid receptor [19], has been reported to
mediate glucocorticoid-induced apoptosis of human leukemia cells
[20]. Moreover, it is also reported to be involved in glucocorticoid-
induced apoptosis of human osteoblast-like cells [21]. Besides
GZMA, GILZ, an ubiquitous protein, whose expression is directly
up-regulated by glucocorticoids, has various interaction with
apoptosis and cell cycle related protein such as SGK1 and FOXO
[21–22]. Based on the above analysis, we assumed these two
protein are involved in DEX induced osteoblast apoptosis and cell
cycle arrest. However, our results illustrated that DEX does not
have an impact on their expression, but can significantly up-
regulate the expression level of P53 and enhance its transcriptional
activity as evident by elevated expression of PUMA, NOXA and
p21.
The crosstalk between GR and P53 has long been a dubious
topic for quite some time. Many studies verified that GR activation
strengthens the transcriptional activity of p53. In a neural cell line
HT-22, GR activation by DEX enhances the transcriptional
activity of p53, and thus induces apoptosis and cell cycle arrest [9].
In human lung carcinoma cells, suppression of p53 blocks DEX-
induced p21 (WAF1/Cip1) over-expression and G1 growth arrest
[23]. In consistent with these studies, Murphy and colleagues
demonstrated that the loss of p53 impairs transcription of GR
target genes, and subsequently impaired GCs rescue of death in a
mouse model of LPS shock [24]. These reports suggested that p53
is necessary to GR transactivation and the downstream signal
transduction.
On the contrary, numerous evidence argue that there is
negative cross-talk between GR and p53. Sengupta reported that
GR activation resulted in p53 cytoplasmic sequestration, thus
inhibiting p53’s transcriptional activity [25]. Similarly, Dex has
been shown to induce ubiquitylation of GR and p53, inhibit
transcriptional activity of both proteins in stressful HUVEC and
normal hepatoma cells [26]. Furthermore, It has been shown
that p53-mediated transcriptional activity is inhibited by GR co-
GRasignificantly decreased in the siGR -1, and siGR -2 groups compared to that in the siC groups and FBS groups. SiGR-1 and siGR -2 group: Cells
treated with siRNA molecules siGR -1 and siGR -2, respectively. siC group: Cells treated with a siRNA which had a randomized nucleotide sequence
that had no significant homology to any part of the human genome. FBS group: Cells without any treatment. (C) The level of the cleaved-caspase 3
protein was significantly up-regulated in the DEX group, when compared to that in the control group, the siGR-1 group,DEX+ siGR-1 group. (D)
Visualization of apoptotic cells by the TUNEL (DAB/haemotox) assay in MC3T3-E1 cells. The cell nuclei was stained with DAPI (blue) (49,6-diamidino-2-
phenylindole).And the apoptotic cells were visualized by TUNEL staining(brown). The apoptotic cells in DEX group is significantly increased compared
to the control group, the siGR-1 group,DEX+siGR-1 group. (E) Assessment of apoptosis in MC3T3-E1 cell using flow cytometry with Annexin V-FITC/PI
staining. Annexin V-FITC(+)PI(2) cells were considered as early apoptotic cells. The apoptotic cells to total cells ratio was significantly (P,0.05) higher
in DEX group compared to the control group, the siGR-1 group,DEX+siGR-1 group. (F) Cell cycle analysis using flow cytometry with PI staining,
showing representive histograms of MC3T3-E1 cells in control group, DEX group, the siGR-1 group,DEX+ siGR-1 group. The proportion of cells in the S
phase decreased markedly in the DEX group in comparison to the control group, the siGR-1 group,DEX+ siGR-1 group. The proportion of cells in the
G0–G1 significantly increased in the DEX group. (P,0.05) Control group: cells treated with PBS. DEX group: cells cells treated with 1 mmol/L
dexamethasone. siGR-1 group: cells treated with siRNA molecules siGR -1. DEX+ siGR-1 group: cells cells treated with 1mmol/L dexamethasone plus
siRNA molecules siGR -1.
doi:10.1371/journal.pone.0037030.g003
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e37030Figure 4. p53 but not granzyme A or GILZ is up-regulated by DEX treatment. (A) Western blot analysis to describe the levels of the proteins
Granzyme A, GILZ and P53 in the MC3T3-E1 cells treated with 0, 0.001,0.01,0.1, 1.0 and 10.0 mmol/L dexamethasone for 24 hours. The levels of
granzyme A and GILZ did not vary significantly between the groups, and the expression of P53 was dose-dependently up-regulated. (B) Western blot
analysis to describe the levels of the proteins NOXA, PUMA, p53 and p21 in the MC3T3-E1 cells. The molecular weight markers were 53 kDa (P52),
21 kDa (p21), 18 kDa (nonspecific PUMA), 24 kDa (specific PUMA), and 15 kDa (NOXA). Control group: cells treated with PBS. DEX group: cells cells
treated with 1 mmol/L dexamethasone. siGR-1 group: cells treated with siRNA molecules siGR -1. DEX+siGR-1 group: cells cells treated with 1 mmol/L
dexamethasone plus siRNA molecules siGR-1.
doi:10.1371/journal.pone.0037030.g004
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e37030Figure 5. p53 gene silienc by siRNA can reverse DEX induced apoptosis and cell cycle arrest of MC3T3-E1 cells. (A) Real time PCR
examination of MC3T3-E1 cells in which the p53 gene function was silenced by siRNA (sip53-1, sip53-2) targeting p53mRNA; the mRNA expression level
of p53 in the sip53-1and sip53-2 groups decreased significantly (P,0.05) compared to that in the FBS group and the siC group. (B) Examination of the
protein expression level of the p53agene by Western blotting following treatment with the indicated siRNA molecules sip53-1 and sip53-2. The protein
expression level of P53significantly decreased in the sip53-1,andsip53-2 groups comparedto that in thesiC groups andFBSgroups. Sip53-1andsip53
-2 group:Cells treated with siRNA molecules sip53-1 andsip53 -2, respectively. siCgroup: Cells treated with a siRNAwhich hada randomized nucleotide
sequence that had no significant homology to any part of the human genome. FBS group: Cells without any treatment. (C) The level of the cleaved-
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transcriptional activity [27]. These studies confirmed that mutual
inhibition between GR and p53 existed in some cell types in
some specific condition.
And some other studies have also propounded that there is no
relationship between p53 and GR. Dex efficiently suppressed TNF
alpha-induced apoptosis through abrogated Bcl-2 reduction,
which is independent of p53’s status [28]. In a similar manner,
irrespective of p53 status, mammalian target of rapamycin
inhibitors sensitize multiple myeloma cells to dexamethasone-
induced apoptosis [29].
In this study, we have illustrated that GR activation by
dexamethasone up-regulates the expression level of P53, enhances
its transcriptional activity, thus resulting in p21, PUMA and
NOXA up-regulation. And this subsequently induces osteoblast
cell cycle arrest and apoptosis. Furthermore, we verified that
disruption of p53 activation by p53 siRNA leads to the decrease in
the DEX-induced cytotoxic and apoptotic activities in osteoblast
cells.
The tumor suppressor p53 provides exquisite decision between
cell growth arrest and apoptosis in response to various cellular
stress. Sustained stress or irreparable damage trigger p539s killer
functions to initiate transcription of pro-apoptotic genes such as
Puma, Noxa, Bax, and Bid. To prevent the unnecessary loss of
cells which could cause premature aging, the killer functions of p53
are tightly regulated and balanced against protector functions that
arrest cell cycle and support survival in response to low stress or
mild damage [30–31]. Our results showed GR activation can up-
regulate P53 expression and transcriptional activity, which
paralleled with cell cycle arrest and apoptosis. While MC3T3-E1
cells (have functional GR and p53) were readily arrested in G1
phase and undergone apoptosis in response to DEX treatment, the
GR-silent and p53-silent MC3T3-E1 cells preceded into S phase
and survived in the presence of DEX. These results demonstrated
that both GR and P53 is necessary for GC induced osteoblast
apoptosis and cell cycle arrest. Furthermore, western blot results
have verified transcriptional activity of p53 is dependent on GR
activation.
In conclusion, our findings suggested that GR activation by
DEX can up-regulate P53, which then enhances its transcriptional
activatity. This mechanism contribute to apoptosis and cell cycle
arrest of MC3T3-E1 cells. P53 could be used as a new target for
the treatment of GC-induced osteoporosis and osteonecrosis.
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